Rasna Therapeutics Company Executives
| RASP Stock | USD 0 0 900.00% |
Rasna Therapeutics employs about 13 people. The company is managed by 2 executives with a total tenure of roughly 31 years, averaging almost 15.0 years of service per executive, having 6.5 employees per reported executive. Discussion of Rasna Therapeutics' management performance can provide insight into the enterprise performance.
| Keeren Shah Insider F Director |
| Willy Simon Insider Ex Chairman |
Rasna |
Rasna Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (3.6957) % which means that it has lost $3.6957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9359) %, meaning that it created substantial loss on money invested by shareholders. Rasna Therapeutics' management efficiency ratios could be used to measure how well Rasna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Rasna Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Rasna Therapeutics Price Series Summation is a cross summation of Rasna Therapeutics price series and its benchmark/peer.
Rasna Therapeutics Notable Stakeholders
A Rasna Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rasna Therapeutics often face trade-offs trying to please all of them. Rasna Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rasna Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Keeren Shah | F Director | Profile | |
| Willy Simon | Ex Chairman | Profile |
About Rasna Therapeutics Management Performance
The success or failure of an entity such as Rasna Therapeutics often depends on how effective the management is. Rasna Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rasna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rasna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Rasna Therapeutics Workforce Analysis
Traditionally, organizations such as Rasna Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rasna Therapeutics within its industry.Rasna Therapeutics Manpower Efficiency
Return on Rasna Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 52.8K | |
| Net Loss Per Executive | 343.3K |
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.